Multimodal treatment interventions may be necessary to improve recovery among patients with TBI.
Patients with traumatic brain injury (TBI) who were treated with citicoline failed to show improvements in functional and cognitive status, according to results of a multicenter phase III trial reported in the November 21, 2012, issue of JAMA. Citicoline proved to be no better than placebo at improving function or cognition after TBI in the first large randomized clinical trial to test it in this patient population.
Citicoline, an endogenous compound that is an intermediate in the biosynthesis of phosphatidylcholine from choline, is thought to have a range of neuroprotective properties and has been approved as a treatment for TBI in 59 countries other than the United States. But it is widely available in the US as a nutraceutical used for various neurologic disorders, said lead author Ross D. Zafonte, DO, of the Department of Physical Medicine and Rehabilitation at Harvard Medical School in Boston, and his associates.